From Monoamines to Systems Psychiatry: Rewiring Depression Science and Care (1960s-2025)

Area of Science:

• Neuroscience
• Psychiatry
• Systems Biology

Background:

• Major depressive disorder (MDD) was historically viewed as a singular condition driven by a linear stress-monoamine-hypothalamic-pituitary-adrenal (HPA) axis pathway.
• Traditional animal models and short-term symptom scales (e.g., HAM-D, MADRS) provided limited translational benefit due to oversimplification.
• Advances in neuroimaging, immune-metabolic profiling, and sleep studies reveal diverse biological patterns and circuit-level dysfunctions in different depressive presentations, explaining high non-response and relapse rates.

Purpose of the Study:

• To challenge the "unitary cascade" model of depression by highlighting its heterogeneity.
• To advocate for a shift from traditional models to a systems psychiatry approach for understanding and treating depression.
• To propose a plasticity-centered framework for depression research and clinical practice.

Main Methods:

• Review of neuroimaging, immune-metabolic, sleep phenotyping, and plasticity marker data.
• Analysis of cross-species translational research, including EEG motifs and effort-based reward tasks.
• Examination of current clinical practices and emerging treatment strategies for depression.

Main Results:

• Depression presents with divergent circuit-level, inflammatory, and chronobiological patterns, indicating distinct patient subgroups.
• Cross-species translational research (e.g., EEG, REM sleep, reward tasks) offers mechanistically grounded insights.
• Current depression care is evolving towards systems psychiatry, incorporating personalized approaches like neuromodulation and digital phenotyping.

Conclusions:

• The heterogeneity of depression necessitates a move beyond simplistic models towards a systems-based understanding.
• A plasticity-centered systems psychiatry approach, integrating biological markers and circuit-level data, holds promise for personalized treatment.
• Future research should focus on hybrid effectiveness-implementation platforms that embed diverse monitoring tools under standardized data protocols to address treatment resistance and improve patient outcomes.